What is BillionToOne?
BillionToOne specializes in the development of its patent-pending QCT molecular counter platform, a unique technological advancement capable of counting DNA molecules at the single-count level. By enhancing the accuracy and accessibility of molecular diagnostics, the company has established a significant footprint in the healthcare sector. Its flagship product, UNITY, represents a breakthrough in prenatal care, enabling the detection of cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies through maternal blood. This innovation positions the company as a critical player in the shift toward more efficient, noninvasive clinical diagnostics.
How much funding has BillionToOne raised?
BillionToOne has raised a total of $646.6M across 6 funding rounds:
Series A
$15M
Series B
$55M
Series C
$125M
Unspecified
$48.5M
Series D
$130M
IPO
$273.1M
Series A (2019): $15M with participation from Hummingbird Ventures, Y Combinator, HOF Capital, 500 Startups Istanbul, NeoTribe Ventures, Libertus Capital, Civilization Ventures, and Pacific 8 Ventures
Series B (2021): $55M, investors not publicly disclosed
Series C (2022): $125M supported by Baillie Gifford, Neotribe Ventures, Adams Street Partners, and Hummingbird Ventures
Unspecified (2022): $48.5M featuring Libertus Capital, Hummingbird Ventures, Adams Street Partners, Baillie Gifford, and Neotribe Ventures
Series D (2024): $130M, investors not publicly disclosed
IPO (2025): $273.1M, investors not publicly disclosed
Key Investors in BillionToOne
Neotribe Ventures
A Silicon Valley-based venture capital firm that identifies and funds entrepreneurs developing breakthrough technologies with the potential to create transformative market movements.
Hummingbird Ventures
A global seed investment fund that focuses on investing in outlier founders at the earliest stages of their ventures, providing significant support throughout the company lifecycle.
Adams Street Partners
A private markets investment management firm founded in 1972 that provides global investment services across various stages of company growth.
What's next for BillionToOne?
With the support of major institutional backers, BillionToOne is poised to scale its diagnostic operations and expand the clinical applications of its QCT platform. The recent capital infusion provides the necessary runway to accelerate research and development, potentially broadening the scope of its screening capabilities beyond current offerings. As the company matures, the focus will likely shift toward commercial expansion and the integration of its molecular counting technology into standard clinical workflows, further solidifying its role as a transformative force in precision medicine.
See full BillionToOne company page
